Stocktoria
Corvus Pharmaceuticals, Inc. CRVS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-03-23
Corvus Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2025 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| R&D expense | $33.7M | — | — | $19.4M | $16.5M |
| Operating income | -$43.0M | — | — | -$27.5M | -$23.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.3M | — | — | -$62.3M | -$27.0M |
| EPS (diluted) | $-0.53 | — | — | $-1.02 | $-0.56 |
| Operating cash flow | -$32.8M | — | — | -$25.4M | -$23.9M |
| Free cash flow | -$33.0M | — | — | — | -$24.0M |
| Cash & equivalents | $4.6M | $14.7M | $5.0M | $8.7M | $12.6M |
| Total assets | $71.1M | $89.5M | $59.4M | $68.9M | $45.6M |
| Total liabilities | $9.9M | $9.2M | $10.1M | $36.3M | $6.9M |
| Shareholders' equity | $61.2M | $80.2M | $49.3M | $32.6M | $38.7M |
Source: SEC EDGAR filings · CIK 0001626971 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.